Safety and biological activity of repeated doses of recombinant human Flt3 ligand in patients with bone scan-negative hormone-refractory prostate cancer.
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology; D019002:CD56 Antigen / Q000096:biosynthesis; D003713:Dendritic Cells / Q000378:metabolism; D019008:Drug Resistance, Neoplasm; D005434:Flow Cytometry; D006412:Hematopoietic Stem Cells / Q000378:metabolism; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000378:metabolism; D008214:Lymphocytes / Q000166:cytology / Q000378:metabolism; D008297:Male; D008565:Membrane Proteins / Q000008:administration & dosage* / Q000378:metabolism*; D008875:Middle Aged; D009000:Monocytes / Q000378:metabolism; D010919:Placebos; D017430:Prostate-Specific Antigen / Q000096:biosynthesis; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D011897:Random Allocation; D011994:Recombinant Proteins / Q000737:chemistry / Q000494:pharmacology*; D013997:Time Factors
D018931:Antineoplastic Agents, Hormonal; D019002:CD56 Antigen; D008565:Membrane Proteins; D010919:Placebos; D011994:Recombinant Proteins; C084881:flt3 ligand protein; D017430:Prostate-Specific Antigen